Tranzone secures GSK deal

Published: 8-Dec-2011
Finance Logistics

Will store various products in Jebel Ali for distribution to the Gulf and Near East Region

Tranzone Logistics, a subsidiary of Saudia Arabia-based Banaja Holdings, is to store various products for GlaxoSmithKline in its new warehouse in Jebel Ali for distribution to the Gulf and Near East Region.

The deal was signed during the opening ceremony for Tranzone’s new facility.

GSK will occupy a major part of Tranzone’s warehouse, contributing approximately 25% of revenue in 2012.

Tranzone said GSK had demanded top-of-the-range facilities and back up to protect products at all times and in all circumstances. Emphasis had also been placed on physical security such as access control and fire prevention and process quality.

Tranzone’s state-of-the-art 3PL warehouse at JAFZA in Jebel Ali provides storage, inventory management, as well as purchasing and re-invoicing to the distributor, all at one convenient location. The firm says it is able to store pharmaceuticals in an ideal environment, and its integrated system better links principals with distributors, removes layers of inefficiency and cuts costs while improving service quality.

See more

You may also like

Manufacturing

Banaja takes majority stake in DEEF Pharmaceutical

Read more
Aims to expand and diversify DEEF facility in Saudi Arabia

Trending Articles

  1. European life sciences investors kick off 2026 with targeted bets on immunity, oncology and metabolic health From thymus regeneration and ECM-targeted oncology to fast-scaling metabolic health technology, three European companies secure fresh capital as investors double down on differentiated science with clear commercial momentum
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    From pilots to production: what 2026 could mean for pharma This editorial examines predictions from the HSBC Innovation Banking Life Sciences and Healthcare team on how innovation, investment and consolidation are expected to shape the market in 2026
  3. Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation The long-term funding will enable the BioInnovation Institute to expand into new scientific fields and European markets, strengthening translation of academic research into commercial life sciences innovation
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    From stockpiles to smart supply chains: how industry wants to fix Europe’s drug shortages An EU-level stockpile may work, but only if it’s flexible, closely monitored and built with logistics in mind. Industry players say drug security will depend less on volume and more on data, digital oversight and early collaboration throughout the supply chain
  5. EIB and Angelini Ventures launch €150m fund to boost European biotech, medtech and digital health startups The EIB and Angelini Ventures will co-invest €150 million to scale innovative European healthtech companies. The deal marks the EIB’s first partnership with a corporate venture capital fund in the healthcare sector

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Manufacturing

Banaja takes majority stake in DEEF Pharmaceutical

Aims to expand and diversify DEEF facility in Saudi Arabia
Finance

Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

Syngene International, a global contract research, development, and manufacturing organisation (CRDMO), announces the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035
Finance

Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation

The long-term funding will enable the BioInnovation Institute to expand into new scientific fields and European markets, strengthening translation of academic research into commercial life sciences innovation
Finance

European life sciences investors kick off 2026 with targeted bets on immunity, oncology and metabolic health

From thymus regeneration and ECM-targeted oncology to fast-scaling metabolic health technology, three European companies secure fresh capital as investors double down on differentiated science with clear commercial momentum
You need to be a subscriber to read this article.
Click here to find out more.
Finance

From pilots to production: what 2026 could mean for pharma

This editorial examines predictions from the HSBC Innovation Banking Life Sciences and Healthcare team on how innovation, investment and consolidation are expected to shape the market in 2026
Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Finance

Symbiosis begins commercial manufacturing at new FDA-inspected facility

Symbiosis Pharmaceutical Services (Symbiosis), a leading sterile fill-finish contract manufacturing organisation (CMO), has manufactured its first 10,000-vial batch at the company’s new facility in Stirling, UK
Subscribe now